SCPH

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-958.9K ExitQ4 2025 $959k -- $5.67
Jim SimonsRenaissance Technologies $-131.6K ExitQ4 2025 $132k -- $5.67
Ken GriffinCitadel Advisors $463.3K AddQ3 2025 $463k -- $5.67
Ken GriffinCitadel Advisors $286.3K AddQ2 2025 $286k -- $5.67
Ken GriffinCitadel Advisors $-671 TrimQ1 2025 $671 -- $5.67
Ken GriffinCitadel Advisors $-2.3M TrimQ4 2024 $2M -- $5.67

Insider Trades

Name	Value	Action	Price	Current Price
Orbimed Advisors LLC10 Percent Owner $2M478.3k shares BuyAug 13, 2024 $4.00 $5.67
Orbimed Advisors LLC10 Percent Owner $87k21.7k shares BuyAug 13, 2024 $4.00 $5.67

Trade SCPH

About scPharmaceuticals Inc.

scPharmaceuticals Inc. is a pharmaceutical firm dedicated to developing and commercializing a variety of medicinal products. Its primary investigational therapy, FUROSCIX, is a specialized formulation of furosemide delivered through an on-body infusor, intended for managing congestion in heart failure patients. The company's pipeline also encompasses scCeftriaxone, an antibiotic aimed at treating infections caused by both gram-positive and gram-negative bacteria, as well as the scCarbapenem program, another antibiotic designed for gram-negative bacterial infections. Additionally, scPharmaceuticals has entered into a collaboration agreement with West Pharmaceutical Services, Inc. for the advancement of a single-use SmartDose device. Founded in 2013, the company's main operations are based in Burlington, Massachusetts.

CEO: John H. Tucker
IPO Date: Nov 17, 2017

Market Data

Open: $5.67
High: $5.67
Low: $5.67
Volume: 10.9M
Avg Volume: 1.4M
52W High: $6.28
52W Low: $1.94

Valuation

Market Cap: $302.2M
Enterprise Value: $313.8M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$70.6M
Revenue: $36.3M
Net Income: -$85.1M
Cash: $75.7M
Debt: $52.7M

Events

EarningsNov 12

EPS est. -0.25 · actual -0.37